Search Results - "Ross, Trenton T"

Murine HSD17β13 does not control liver steatosis and modestly impacts fibrosis in a sex- and diet-specific manner by Crane, Justin D., Barrandon, Ornella, Faherty, Bryan, Gorgoglione, Matt, Crowley, Collin, Morin, Jeff, Ross, Trenton T., Shimkonis, Jackson, Li, Dongmei, Hirenallur-Shanthappa, Dinesh, Boucher, Magalie, Ahn, Youngwook, Clasquin, Michelle F.

“…Human genetic studies show that loss of function mutations in 17-Beta hydroxysteroid dehydrogenase (HSD17β13) are associated with protection from non-alcoholic…”
Get full text

The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes by Linden, Melissa A., Ross, Trenton T., Beebe, David A., Gorgoglione, Matthew F., Hamilton, Karyn L., Miller, Benjamin F., Braun, Barry, Esler, William P.

“…Exercise is recommended in addition to pharmacotherapies for the management of type 2 diabetes, but metformin and exercise training may have non-additive or…”
Get full text

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction by Gutierrez, Jemy A., Liu, Wei, Perez, Sylvie, Xing, Gang, Sonnenberg, Gabriele, Kou, Kou, Blatnik, Matt, Allen, Richard, Weng, Yan, Vera, Nicholas B., Chidsey, Kristin, Bergman, Arthur, Somayaji, Veena, Crowley, Collin, Clasquin, Michelle F., Nigam, Anu, Fulham, Melissa A., Erion, Derek M., Ross, Trenton T., Esler, William P., Magee, Thomas V., Pfefferkorn, Jeffrey A., Bence, Kendra K., Birnbaum, Morris J., Tesz, Gregory J.

“…Recent studies suggest that excess dietary fructose contributes to metabolic dysfunction by promoting insulin resistance, de novo lipogenesis (DNL), and…”
Get full text

The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats by Erion, Derek M, Lapworth, Amanda, Amor, Paul A, Bai, Guoyun, Vera, Nicholas B, Clark, Ronald W, Yan, Qingyun, Zhu, Yimin, Ross, Trenton T, Purkal, Julie, Gorgoglione, Matthew, Zhang, Guodong, Bonato, Vinicius, Baker, Levenia, Barucci, Nicole, D'Aquila, Theresa, Robertson, Alan, Aiello, Robert J, Yan, Jiangli, Trimmer, Jeff, Rolph, Timothy P, Pfefferkorn, Jeffrey A

“…Hyperglycemia resulting from type 2 diabetes mellitus (T2DM) is the main cause of diabetic complications such as retinopathy and neuropathy. A reduction in…”
Get full text

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK) by Huard, Kim, Ahn, Kay, Amor, Paul, Beebe, David A, Borzilleri, Kris A, Chrunyk, Boris A, Coffey, Steven B, Cong, Yang, Conn, Edward L, Culp, Jeffrey S, Dowling, Matthew S, Gorgoglione, Matthew F, Gutierrez, Jemy A, Knafels, John D, Lachapelle, Erik A, Pandit, Jayvardhan, Parris, Kevin D, Perez, Sylvie, Pfefferkorn, Jeffrey A, Price, David A, Raymer, Brian, Ross, Trenton T, Shavnya, Andre, Smith, Aaron C, Subashi, Timothy A, Tesz, Gregory J, Thuma, Benjamin A, Tu, Meihua, Weaver, John D, Weng, Yan, Withka, Jane M, Xing, Gang, Magee, Thomas V

“…Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in…”
Get full text

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials by Calle, Roberto A., Amin, Neeta B., Carvajal-Gonzalez, Santos, Ross, Trenton T., Bergman, Arthur, Aggarwal, Sudeepta, Crowley, Collin, Rinaldi, Anthony, Mancuso, Jessica, Aggarwal, Naresh, Somayaji, Veena, Inglot, Malgorzata, Tuthill, Theresa A., Kou, Kou, Boucher, Magalie, Tesz, Greg, Dullea, Robert, Bence, Kendra K., Kim, Albert M., Pfefferkorn, Jeffrey A., Esler, William P.

“…Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are…”
Get full text

Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis by Futatsugi, Kentaro, Cabral, Shawn, Kung, Daniel W., Huard, Kim, Lee, Esther, Boehm, Markus, Bauman, Jonathan, Clark, Ronald W., Coffey, Steven B., Crowley, Collin, Dechert-Schmitt, Anne-Marie, Dowling, Matthew S., Dullea, Robert, Gosset, James R., Kalgutkar, Amit S., Kou, Kou, Li, Qifang, Lian, Yajing, Loria, Paula M., Londregan, Allyn T., Niosi, Mark, Orozco, Christine, Pettersen, John C., Pfefferkorn, Jeffrey A., Polivkova, Jana, Ross, Trenton T., Sharma, Raman, Stock, Ingrid A., Tesz, Gregory, Wisniewska, Hanna, Goodwin, Bryan, Price, David A.

“…Discovery efforts leading to the identification of ervogastat (PF-06865571), a systemically acting diacylglycerol acyltransferase (DGAT2) inhibitor that has…”
Get full text

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems by Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.

“…Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA…”
Get full text

Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting by Huard, Kim, Smith, Aaron C, Cappon, Gregg, Dow, Robert L, Edmonds, David J, El-Kattan, Ayman, Esler, William P, Fernando, Dilinie P, Griffith, David A, Kalgutkar, Amit S, Ross, Trenton T, Bagley, Scott W, Beebe, David, Bi, Yi-An, Cabral, Shawn, Crowley, Collin, Doran, Shawn D, Dowling, Matthew S, Liras, Spiros, Mascitti, Vincent, Niosi, Mark, Pfefferkorn, Jeffrey A, Polivkova, Jana, Préville, Cathy, Price, David A, Shavnya, Andre, Shirai, Norimitsu, Smith, Andrew H, Southers, James R, Tess, David A, Thuma, Benjamin A, Varma, Manthena V, Yang, Xiaojing

“…Preclinical and clinical data suggest that acetyl-CoA carboxylase (ACC) inhibitors have the potential to rebalance disordered lipid metabolism, leading to…”
Get full text

Inhibition of Acetyl-CoA Carboxylase Causes Malformations in Rats and Rabbits: Comparison of Mammalian Findings and Alternative Assays by Catlin, Natasha R, Bowman, Christopher J, Campion, Sarah N, Davenport, Scott D, Esler, William P, Kumpf, Steven W, Lewis, Elise M, Nowland, William S, Ross, Trenton T, Stedman, Donald S, Stethem, Christine, Cappon, Gregg D

“…Abstract Acetyl-CoA carboxylase (ACC) is an enzyme within the de novo lipogenesis (DNL) pathway and plays a role in regulating lipid metabolism. Pharmacologic…”
Get full text

GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner by Smith, Kathleen R, Wang, Wenshan, Miller, Melissa R, Boucher, Magalie, Reynold, Jessica E, Daurio, Natalie A, Li, Dongmei, Hirenallur-Shanthappa, Dinesh, Ahn, Youngwook, Beebe, David A, Kelly, Kenneth L, Ross, Trenton T, Bence, Kendra K, Wan, Min

“…Nonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver…”
Get full text

De novo lipogenesis is essential for platelet production in humans by Kelly, Kenneth L., Reagan, William J., Sonnenberg, Gabriele E., Clasquin, Michelle, Hales, Katherine, Asano, Shoh, Amor, Paul A., Carvajal-Gonzalez, Santos, Shirai, Norimitsu, Matthews, Marcy D., Li, Kelvin W., Hellerstein, Marc K., Vera, Nicholas B., Ross, Trenton T., Cappon, Gregg, Bergman, Arthur, Buckeridge, Clare, Sun, Zhongyuan, Qejvanaj, Enida Ziso, Schmahai, Theodore, Beebe, David, Pfefferkorn, Jeffrey A., Esler, William P.

“…Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic…”
Get full text

β‐GPA treatment leads to elevated basal metabolic rate and enhanced hypoxic exercise tolerance in mice by Ross, Trenton T., Overton, Jeffrey D., Houmard, Katelyn F., Kinsey, Stephen T.

“…Treatments that increase basal metabolic rate (BMR) and enhance exercise capacity may be useful therapeutic approaches for treating conditions such as type 2…”
Get full text

Combined Exercise Training and Sodium‐glucose Cotransporter 2 Inhibition Improves Glycemic Control and Exercise Tolerance When Compared to Pharmacotherapy Alone in a Model of Type 2 Diabetes by Linden, Melissa A., Ross, Trenton T., Beebe, David A., Hamilton, Karyn L., Miller, Benjamin F., Braun, Barry, Esler, William P.

“…Regular exercise (EX) is recommended in addition to pharmacotherapies for the management of type 2 diabetes (T2D), but patients with T2D often have difficulty…”
Get full text

Comparison of the Therapeutic Effects of the Combination of Exercise Training with Either a Sodium‐glucose Cotransporter 2 Inhibitor or Metformin in a Murine Model of Type 2 Diabetes by Linden, Melissa A., Ross, Trenton T., Hamilton, Karyn L., Miller, Benjamin F., Braun, Barry, Esler, William P.

“…Abstract only Pharmacotherapy and lifestyle modifications, including regular exercise (EX), are recommended for the management of type 2 diabetes mellitus…”
Get full text

Recent advances in drug transporter sciences: highlights from the year 2020 by Chothe, Paresh P., Nakakariya, Masanori, Rotter, Charles J., Sandoval, Philip, Tohyama, Kimio

“…Drug Metabolism Reviews has an impressive track record of providing scientific reviews in the area of xenobiotic biotransformation over 47 years. It has…”
Get full text

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model SystemsSummary by Trenton T. Ross, Collin Crowley, Kenneth L. Kelly, Anthony Rinaldi, David A. Beebe, Matthew P. Lech, Robert V. Martinez, Santos Carvajal-Gonzalez, Magalie Boucher, Dinesh Hirenallur-Shanthappa, Jeffrey Morin, Alan C. Opsahl, Sarah R. Vargas, Kendra K. Bence, Jeffrey A. Pfefferkorn, William P. Esler

“…Background & Aims: Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH)…”
Get full text